(UroToday.com) The Society of Urologic Oncology (SUO) annual winter meeting included an advanced prostate cancer session and a presentation by Dr. Michael Morris discussing the VISION trial and integration of PSMA-targeted therapy for advanced prostate cancer. Dr. Morris notes that radioligand therapy has undergone an evolution in targeting from hydroxyapatite targeting to tumor targeting. Based on 2020 data estimating the market sales ($11.2 billion) by drug class for advanced prostate cancer, there has been limited use ($0.3 billion) of bone metastases-targeted agents:

X